Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017096458) IMMUNE GENE SIGNATURE PREDICTIVE OF ANTHRACYCLINE BENEFIT
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/096458 International Application No.: PCT/CA2016/000305
Publication Date: 15.06.2017 International Filing Date: 07.12.2016
IPC:
C40B 40/06 (2006.01) ,C12Q 1/68 (2006.01) ,C40B 30/04 (2006.01) ,G01N 33/48 (2006.01) ,G06F 19/10 (2011.01) ,G06F 19/20 (2011.01)
C CHEMISTRY; METALLURGY
40
COMBINATORIAL TECHNOLOGY
B
COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES
40
Libraries per se, e.g. arrays, mixtures
04
Libraries containing only organic compounds
06
Libraries containing nucleotides or polynucleotides, or derivatives thereof
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
C CHEMISTRY; METALLURGY
40
COMBINATORIAL TECHNOLOGY
B
COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES
30
Methods of screening libraries
04
by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
G PHYSICS
06
COMPUTING; CALCULATING; COUNTING
F
ELECTRIC DIGITAL DATA PROCESSING
19
Digital computing or data processing equipment or methods, specially adapted for specific applications
10
Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
G PHYSICS
06
COMPUTING; CALCULATING; COUNTING
F
ELECTRIC DIGITAL DATA PROCESSING
19
Digital computing or data processing equipment or methods, specially adapted for specific applications
10
Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
20
for hybridisation or gene expression, e.g. microarrays, sequencing by hybridisation, normalisation, profiling, noise correction models, expression ratio estimation, probe design or probe optimisation
Applicants:
ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) [CA/CA]; 661 University Avenue Suite 510 Toronto, Ontario M5G 0A3, CA
Inventors:
BRAUNSTEIN, Marsela; CA
BARTLETT, John, MS; CA
YAO, Cindy; CA
SPEARS, Melanie; CA
Agent:
CHIU, Jung-Kay; Norton Rose Fulbright Canada LLP 1 Place Ville Marie, Suite 2500 Montreal, Quebec H3B 1R1, CA
Priority Data:
62/263,83107.12.2015US
62/264,02907.12.2015US
Title (EN) IMMUNE GENE SIGNATURE PREDICTIVE OF ANTHRACYCLINE BENEFIT
(FR) SIGNATURE GÉNIQUE IMMUNITAIRE PRÉDICTIVE DES BIENFAITS DE L’ANTHRACYCLINE
Abstract:
(EN) There is described herein a method of predicting a benefit of anthracycline therapy for a subject with breast cancer, the method comprising: a) providing a sample of a breast cancer tumour of the subject; b) determining the level of expression in the sample for a group of genes comprising at least 3 of: GZMB, PRF1, SELL, CCL22, CXCL10, CXCL13, IL8, IRF1 and STAT3; c) comparing said expression levels to a reference expression level of the group of genes from control samples from a population; and d) determining the benefit of anthracycline therapy for the subject; wherein a statistically significant difference or similarity in the expression of the group of genes compared to the reference expression level correlates to an immune score; a relatively low immune score being associated with a greater benefit of anthracycline therapy, and a relatively high immune score being associated with a lesser benefit of anthracycline therapy
(FR) L'invention concerne un procédé permettant de prédire les bienfaits d'une thérapie à base d’anthracycline chez un sujet atteint d’un cancer du sein, le procédé comprenant : a) la fourniture d'un échantillon d'une tumeur de cancer du sein du sujet ; b) l’estimation du niveau d'expression dans l'échantillon pour un groupe de gènes comprenant au moins 3 parmi les suivants : GZMB, PRF1, SEL1, CCL22, CXCL10, CXCL13, IL8, IRF1 et STAT3 ; c) la comparaison des niveaux d'expression à un niveau d'expression de référence du groupe de gènes provenant d'échantillons témoins d'une population ; et d) l’estimation des bienfaits d'une thérapie à base d'anthracycline pour le sujet ; une différence ou une similarité statistiquement significative dans l'expression du groupe de gènes par rapport au niveau d'expression de référence étant en corrélation avec une note immunitaire ; une note immunitaire relativement faible étant associée à des bienfaits plus importants d'une thérapie à base d’anthracycline, et une note immunitaire relativement élevée étant associée à des bienfaits moindres d'une thérapie à base d’anthracycline.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)